{"schema_version":"secwatch.filing_event.v1","accession":"0001549595-25-000053","form_type":"8-K","ticker":"NRIX","cik":"0001549595","company_name":"Nurix Therapeutics, Inc.","filed_at":"2025-04-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.722314+00:00","generated_at":"2026-05-23T19:01:43.869139+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Nurix posts Q1 FY2025 net loss $56.4M; bexobrutideg gets orphan drug designation","bullets":["Revenue $18.5M, up from $16.6M YoY; net loss $56.4M ($0.67/share) vs $41.5M prior year.","Cash & marketable securities $549.7M at Feb 28, 2025; down from $609.6M at Nov 30, 2024.","Earned $7M milestones in quarter; post-quarter received $15M license extension fee from Sanofi.","NX-5948 named bexobrutideg; FDA Orphan Drug for Waldenström macroglobulinemia; pivotal trials in CLL on track for 2025.","Added Roy Baynes to board and John Northcott as CCO; Sanofi exercised option to license undisclosed inflammation target."],"urls":{"canonical":"https://secwatch.observer/filing/0001549595-25-000053","json":"https://secwatch.observer/filing/0001549595-25-000053.json","markdown":"https://secwatch.observer/filing/0001549595-25-000053.md","text":"https://secwatch.observer/filing/0001549595-25-000053.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1549595/000154959525000053/0001549595-25-000053-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1549595/000154959525000053/nrix-20250408.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T19:01:43.869139+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}